Human Liver-on-a-Chip Systems for Enhanced Mechanism-Based Toxicity Screening

Background and Purpose

High-quality hepatocytes are essential for in vitro toxicology studies because they recapitulate critical liver functions, including metabolism, detoxification, and drug response. Their integration into advanced model systems improves prediction of drug-induced liver injury (DILI), reduces reliance on animal models, and enables early identification of hepatotoxic compounds. This study evaluated cryopreserved HepatoXcell™ Pro hepatocytes within a liver-on-a-chip platform under dynamic, physiologically relevant conditions, aiming to establish a robust system for predictive toxicology and pharmacokinetic assessment. 

Methods

Primary human hepatocytes (HepatoXcell™ Pro) were incorporated into a liver-on-a-chip system featuring 3-D liver tissue architecture within a dynamic fluidic environment. The platform was optimized for hepatocyte viability and function, enabling measurement of liver-specific markers, toxicity-related enzymes, and pharmacokinetic parameters. Standardized protocols were developed to assess drug-induced cytotoxicity via viability assays and enzyme activity profiling. System performance was benchmarked against qualification guidelines for preclinical toxicology models.

Results

The liver-on-a-chip platform maintained hepatocyte morphology and function under dynamic flow conditions. HepatoXcell™ Pro exhibited stable expression of liver-specific markers and metabolic enzymes, supporting accurate assessment of hepatotoxicity. Toxicity testing with therapeutic compounds revealed dose-dependent cytotoxicity and changes in enzyme activity consistent with known DILI profiles. The platform demonstrated reproducibility across multiple runs, meeting qualification criteria for predictive toxicology applications.

Conclusion

Integrating HepatoXcell™ Pro into a liver-on-a-chip system enhances predictive accuracy for DILI and supports mechanism-based toxicity screening in human-relevant models. This approach reduces reliance on animal testing and strengthens early-stage safety assessment, facilitating the development of safer therapeutic agents. Broad adoption of this technology could significantly advance translational toxicology and risk assessment in drug development.